| NET PROFIT (LOSS) PER SHARE The following table sets forth the computation of basic and diluted net profit (loss) per share for the periods indicated (in thousands, except per share data): | | | | | | | | | | | | | Three Months Ended March 31, | | 2026 | | 2025 | | | | | | Net profit - basic | $ | 48,211 | | | $ | 61,790 | | | Changes in fair value of convertible loan | (63,823) | | | (42,934) | | | Net (loss) profit - diluted | $ | (15,612) | | | $ | 18,856 | | | | | | Weighted average common stock used in computing basic net profit per share | 332,360 | | | 323,431 | | | Weighted-average effect of dilutive securities: | | | | | | | | | Diluted effect of shares issuable upon exercise of stock options | — | | | 11 | | | Diluted effect of shares issuable upon exercise of non-vested shares | — | | | 983 | | | Diluted effect of shares issuable upon conversion of convertible loan | 52,912 | | | 50,000 | | Weighted average common stock used in computing diluted net (loss) profit per share | 385,272 | | | 374,425 | | | | | | | Net profit per share - basic | $ | 0.15 | | | $ | 0.19 | | | Net (loss) profit per share - diluted | $ | (0.04) | | | $ | 0.05 | |
Potentially dilutive securities not included in the diluted net profit (loss) per share computations because their effect would have been anti-dilutive were as follows (in thousands): | | | | | | | | | | | | | Three Months Ended March 31, | | 2026 | | 2025 | | Shares issuable upon exercise of stock options | 548 | | | 30,876 | | | Shares issuable upon vesting of non-vested shares | 1,472 | | | 884 | | | Shares issuable upon exercise of warrants | 933 | | | 33,937 | | | Shares issuable that may be subject to cancellation | — | | | 1,688 | |
|